본문 바로가기
KERD
논문KCI 등재

Highlighted STAT3 as a potential drug target for cancer therapy

정애진|이해리|예상규
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2019.07|BMB Reports|제52권 제7호|pp. 415-423|DOI https://doi.org/10.5483/BMBRep.2019.52.7.152

2

조회

0

다운로드

7

인용

0

참고문헌

키워드

Tumor microenvironmentCancer therapySTAT3Cancer stem cellsImmune suppression
주제분류화학

초록

Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that regulates cell proliferation, differentiation, apoptosis, angiogenesis, inflammation and immune responses. Aberrant STAT3 activation triggers tumor progression through oncogenic gene expression in numerous human cancers, leading to promote tumor malignancy. On the contrary, STAT3 activation in immune cells cause elevation of immunosuppressive factors. Accumulating evidence suggests that the tumor microenvironment closely interacts with the STAT3 signaling pathway. So, targeting STAT3 may improve tumor progression, and anti-cancer immune response. In this review, we summarized the role of STAT3 in cancer and the tumor microenvironment, and present inhibitors of STAT3 signaling cascades.

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that regulates cell proliferation, differentiation, apoptosis, angiogenesis, inflammation and immune responses. Aberrant STAT3 activation triggers tumor progression through oncogenic gene expression in numerous human cancers, leading to promote tumor malignancy. On the contrary, STAT3 activation in immune cells cause elevation of immunosuppressive factors. Accumulating evidence suggests that the tumor microenvironment closely interacts with the STAT3 signaling pathway. So, targeting STAT3 may improve tumor progression, and anti-cancer immune response. In this review, we summarized the role of STAT3 in cancer and the tumor microenvironment, and present inhibitors of STAT3 signaling cascades.

참고문헌 (110)

  1. Hanahan D, "Hallmarks of Cancer : The Next Generation", Cell, 144, pp.646~674 (2011)
  2. Yu H, "The STATs of cancer — new molecular targets come of age", Nat Rev Cancer, 4, pp.97~105 (2004)
  3. Chen J, "Inhibition of STAT3Signaling Pathway by Nitidine Chloride Suppressed the Angiogenesis and Growth of Human Gastric Cancer", Mol Cancer Ther, 11, pp.277~287 (2012)
  4. Wang T, "Regulation of the innate and adaptive immune responses by Stat-3signaling in tumor cells", Nat Med, 10, pp.48~54 (2004)
  5. Huynh J, "Therapeutically exploiting STAT3 activity in cancer —using tissue repair as a road map", Nat Rev Cancer, 19, pp.82~96 (2019)
  6. Joyce JA, "T cell exclusion, immune privilege, and the tumor microenvironment", Science, 348, pp.74~80 (2015)
  7. Spill F, "Impact of the physical microenvironment on tumor progression and metastasis", Curr Opin Biotechnol, 40, pp.41~48 (2016)
  8. Herrmann A, "Targeting Stat3 in the Myeloid Compartment Drastically Improves the in vivo Antitumor Functions of Adoptively Transferred T Cells", Cancer Res, 70, pp.7455~7464 (2010)
  9. Kortylewski M, "Role of Stat3 in suppressing anti-tumor immunity", Curr Opin Immunol, 20, pp.228~233 (2008)
  10. Frank DA, "STAT3 as a central mediator of neoplastic cellular transformation", Cancer Lett, 251, pp.199~210 (2007)
  11. Roeser JC, "Emerging strategies for cancer immunoprevention", Oncogene, 34, pp.6029~ (2015)
  12. Sonnenblick A, "Tissue microarray-based study of patients with lymph nodepositive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3(tyrosine705-STAT3)is a marker of good prognosis", Clin Transl Oncol, 14, pp.232~236 (2012)
  13. Schaefer LK, "Constitutive activation of Stat3 in brain tumors : localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor(VEGFR-2)", Oncogene, 21, pp.2058~2065 (2002)
  14. Geiger JL, "The STAT3pathway as a therapeutic target in head and neck cancer : Barriers and innovations", Oral Oncology, 56, pp.84~92 (2016)
  15. Li S, "Icaritin Inhibits JAK", STAT3 Signaling and Growth of Renal Cell Carcinoma, 2013, pp.8, e81657~
  16. He G, "NF-κB and STAT3 – key players in liver inflammation and cancer", Cell Res, 21, pp.159~ (2010)
  17. Saini U, "Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis : a potential therapeutic target", Oncogene, 36, pp.168~ (2016)
  18. Bar-Natan M, "STAT signaling in the pathogenesis and treatment of myeloid malignancies", JAK-STAT, 1, pp.55~64 (2012)
  19. Fukuda A, "Stat3and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression", Cancer Cell, 19, pp.441~455 (2011)
  20. Redell MS, "Stat3 signaling in acute myeloid leukemia : ligand-dependent and-independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor", Blood, 117, pp.5701~5709 (2011)
  21. Alas S, "Inhibition of Constitutive STAT3 Activity Sensitizes Resistant Non-Hodgkin’s Lymphoma and Multiple Myeloma to Chemotherapeutic Drug-mediated Apoptosis", Clin Cancer Res, 9, pp.316~326 (2003)
  22. Yu H, "STATs in cancer inflammation and immunity : a leading role for STAT3", Nat Rev Cancer, 9, pp.798~ (2009)
  23. Bromberg J, "The role of STATs in transcriptional control and their impact on cellular function", Oncogene, 19, pp.2468~2473 (2000)
  24. 김병학, "Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment", Archives of Pharmacal Research, 39(8), pp.1085~1099 (2016), 대한약학회
  25. Horiguchi A, "STAT3, but not ERKs, mediates the IL-6–induced proliferation of renal cancer cells, ACHN and 769P", Kidney Int, 61, pp.926~938 (2002)
  26. Lin L, "STAT3 Is Necessary for Proliferation and Survival in Colon Cancer–Initiating Cells", Cancer Res, 71, pp.7226~7237 (2011)
  27. Corvinus FM, "Persistent STAT3 Activation in Colon Cancer Is Associated with Enhanced Cell Proliferation and Tumor Growth", Neoplasia, 7, pp.545~555 (2005)
  28. Catlett-Falcone R, "Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells", Immunity, 10, pp.105~115 (1999)
  29. Epling-Burnette PK, "Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression", J Clin Invest, 107, pp.351~362 (2001)
  30. Chen H, "Discovery of O-Alkylamino-Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents", ACS Med Chem Lett, 4, pp.180~185 (2013)
  31. Kanai M, "Differentiation-inducing factor-1(DIF-1)inhibits STAT3activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway", Oncogene, 22, pp.548~554 (2003)
  32. Pancotti F, "Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling", Cell Signal, 24, pp.1390~1397 (2012)
  33. Wei D, "Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis", Oncogene, 22, pp.319~329 (2003)
  34. Kujawski M, "Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice", J Clin Invest, 118, pp.3367~3377 (2008)
  35. Xu Q, "Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways", Oncogene, 24, pp.5552~5560 (2005)
  36. Jung JE, "STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells", FASEB J, 19, pp.1296~1298 (2005)
  37. Wojcik EJ, "A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells", Oncogene, 25, pp.2773~2784 (2006)
  38. Cheng GZ, "Twist Is Transcriptionally Induced by Activation of STAT3 and Mediates STAT3 Oncogenic Function", J Biol Chem, 283, pp.14665~14673 (2008)
  39. Banerjee K, "Constitutive activation of STAT3 in breast cancer cells : A review", Int J Cancer, 138, pp.2570~2578 (2016)
  40. Wendt MK, "STAT3 and epithelial-mesenchymal transitions in carcinomas", JAK-STAT, 3, pp.e28975~e28975 (2014)[DOI]
  41. Chen M, "High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21–Mediated Matrix Metalloproteinase Activity", Cancer Res, 75, pp.1645~1656 (2015)
  42. Xiong H, "Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition", J Biol Chem, 287, pp.5819~5832 (2012)
  43. Kalluri R, "Basement membranes : structure, assembly and role in tumour angiogenesis", Nat Rev Cancer, 3, pp.422~433 (2003)
  44. Dechow TN, "Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C", Proc Natl Acad Sci U S A, 101, pp.10602~10607 (2004)
  45. Itoh M, "Requirement of STAT3 activation for maximal collagenase-1(MMP-1)induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells", Oncogene, 25, pp.1195~1204 (2006)
  46. Sano S, "Keratinocytespecific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis", EMBO J, 18, pp.4657~4668 (1999)
  47. Silver DL, "Activated signal transducer and activator of transcription(STAT)3 : localization in focal adhesions and function in ovarian cancer cell motility", Cancer Res, 64, pp.3550~3558 (2004)
  48. Herbeuval J-P, "Recruitment of STAT3 for Production of IL-10 by Colon Carcinoma Cells Induced by Macrophage-Derived IL-6", J Immunol, 172, pp.4630~4636 (2004)
  49. Stumhofer JS, "Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10", Nat Immunol, 8, pp.1363~ (2007)
  50. Saudemont A, "NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells", Blood, 105, pp.2428~2435 (2005)
  51. Thakur R, "Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer", Sci Rep, 5, pp.10194~ (2015)
  52. Blaylock R, "Cancer microenvironment, inflammation and cancer stem cells : A hypothesis for a paradigm change and new targets in cancer control", Surg Neurol Int, 6, pp.92~ (2015)
  53. Liu X, "Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer", Pathol Oncol Res, 18, pp.17~23 (2012)
  54. Wei W, "STAT3Signaling Is Activated Preferentially in Tumor-Initiating Cells in Claudin-Low Models of Human Breast Cancer", Stem Cells, 32, pp.2571~2582 (2014)
  55. Won C, "Signal transducer and activator of transcription 3-mediated CD133up-regulation contributes to promotion of hepatocellular carcinoma", Hepatology, 62, pp.1160~1173 (2015)
  56. Zhang X, "Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6", JAK2, Cell Death Dis, pp.2018, 9[DOI]
  57. Haftchenary S, "Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells : A Promising Route for Treating Glioblastoma", ACS Med Chem Lett, 4, pp.1102~1107 (2013)
  58. Qu Y, "Generation of Prostate Tumor–Initiating Cells Is Associated with Elevation of Reactive Oxygen Species and IL-6", STAT3Signaling, 2013, pp.73, 7090~7100
  59. Hossain A, "Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6", gp130, Stem Cells, pp.2015, 33[DOI]
  60. van der Zee M, "IL6", JAK1, CD126+ Stem-like Component and Reduces Tumor Burden, pp.Cancer Res, 2015[DOI]
  61. Gibbs CP, "Stem-like cells in bone sarcomas: implications for tumorigenesis", Neoplasia (New York, N.Y.), 7, pp.967~976 (2005)
  62. Marotta LLC, "The JAK2", STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors, 2011, pp.121, 2723~2735
  63. Zhao D, "VEGF drives cancer-initiating stem cells through VEGFR-2", Stat3signaling to upregulate Myc and Sox2, 2014, pp.34, 3107~
  64. Tseng L-M, "Targeting Signal Transducer and Activator of Transcription 3Pathway by Cucurbitacin I Diminishes Self-Renewing and Radiochemoresistant Abilities in Thyroid Cancer-Derived CD133+ Cells", J Pharmacol Exp Ther, 341, pp.410~423 (2012)
  65. Groner B, "The function of Stat3 in tumor cells and their microenvironment", Semin Cell Dev Biol, 19, pp.341~350 (2008)
  66. Joo Eun Jung, "STAT3 inhibits the degradation of HIF-1α by pVHL-mediated ubiquitination", Experimental and Molecular Medicine, 40(5), pp.479~485 (2008), 생화학분자생물학회
  67. Samavati L, "STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6production in response to lipopolysaccharide and live bacteria", Mol Immunol, 46, pp.1867~1877 (2009)
  68. Gao H, "Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium", Stem Cells, 27, pp.857~865 (2009)
  69. Fujiwara Y, "A novel strategy for inducing the antitumor effects of triterpenoid compounds : blocking the protumoral functions of tumor-associated macrophages via STAT3 inhibition", Biomed Res Int, 2014, pp.348539~ (2014)
  70. Kim KJ, "STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression", Oncogene, 36, pp.5445~ (2017)
  71. Kujawski M, "Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice", J Clin Invest, 118, pp.3367~3377 (2008)
  72. Wu L, "Signal transducer and activator of transcription 3(Stat3C)promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis", Am J Pathol, 179, pp.2131~2141 (2011)
  73. Sun X, "Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions via Reverse Hepatocellular Carcinoma–Induced Immune Suppression", Mol Cancer Ther, 12, pp.2885~2896 (2013)
  74. Haura EB, "Mechanisms of Disease : insights into the emerging role of signal transducers and activators of transcription in cancer", Nat Clin Pract Oncol, 2, pp.315~324 (2005)
  75. Debnath B, "Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3(Stat3)Protein", J Med Chem, 55, pp.6645~6668 (2012)
  76. Jinxia D, "Small Molecule Inhibitors of Stat3 Signaling Pathway", Curr Cancer Drug Targets, 7, pp.91~107 (2007)
  77. Turkson J, "Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation", J Biol Chem, 276, pp.45443~45455 (2001)
  78. Siddiquee KAZ, "An Oxazole-Based Small-Molecule Stat3 Inhibitor Modulates Stat3 Stability and Processing and Induces Antitumor Cell Effects", ACS Chem Biol, 2, pp.787~798 (2007)
  79. Zhang X, "A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation", Cancer Res, 73, pp.1922~1933 (2013)
  80. Kumar A, "Molecular docking studies on inhibition of Stat3 dimerization by curcumin natural derivatives and its conjugates with amino acids", Bioinformation, 8, pp.988~993 (2012)
  81. Shin D-S, "Cryptotanshinone Inhibits Constitutive Signal Transducer and Activator of Transcription 3 Function through Blocking the Dimerization in DU145 Prostate Cancer Cells", Cancer Res, 69, pp.193~202 (2009)
  82. Song H, "A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells", Proc Natl Acad Sci U S A, 102, pp.4700~4705 (2005)
  83. Schust J, "Stattic : A Small-Molecule Inhibitor of STAT3 Activation and Dimerization", Chem Biol, 13, pp.1235~1242 (2006)
  84. Fletcher S, "Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules", Chem Med Chem, 6, pp.1459~1470 (2011)
  85. Lin Y-M, "HIC1 interacts with and modulates the activity of STAT3", Cell Cycle, 12, pp.2266~2276 (2013)
  86. Turkson J, "Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity", Mol Cancer Ther, 3, pp.1533~1542 (2004)
  87. Nagel-Wolfrum K, "The Interaction of Specific Peptide Aptamers With the DNA Binding Domain and the Dimerization Domain of the Transcription Factor Stat3 Inhibits Transactivation and Induces Apoptosis in Tumor Cells", Mol Cancer Res, 2, pp.170~182 (2004)
  88. Buerger C, "Sequence-specific Peptide Aptamers, Interacting with the Intracellular Domain of the Epidermal Growth Factor Receptor, Interfere with Stat3 Activation and Inhibit the Growth of Tumor Cells", J Biol Chem, 278, pp.37610~37621 (2003)
  89. Ge H, "Therapeutic and Preventive Effects of an Epidermal Growth Factor Receptor Inhibitor on Oral Squamous Cell Carcinoma", J Int Med Res, 40, pp.455~466 (2012)
  90. Huang C, "Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro", Cancer Sci, 97, pp.1417~1423 (2006)
  91. Ferrajoli A, "WP1066Disrupts Janus Kinase-2 and Induces Caspase-Dependent Apoptosis in Acute Myelogenous Leukemia Cells", Cancer Res, 67, pp.11291~11299 (2007)
  92. Pardanani A, "TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L", K mutations, 2007, pp.21, 1658~
  93. Scuto A, "The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3signaling, resulting in suppression of human myeloma cell growth and survival", Leukemia, 25, pp.538~ (2010)
  94. Yan S, "Inhibition of STAT3with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo", Oncotarget, 4, pp.433~445 (2013)
  95. Chen Z, "Potent Inhibition of Platelet-Derived Growth Factor-Induced Responses in Vascular Smooth Muscle Cells by BMS-354825(Dasatinib)", Mol Pharmacol, 69, pp.1527~1533 (2006)
  96. Michels S, "SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells", Cancer Res, 73, pp.2518~2528 (2013)
  97. Chang AY, "Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib(BMS-354825)on hepatocellular carcinoma cells", BMC Cancer, 13, pp.267~ (2013)
  98. Premkumar D, "Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells", J Carcinog, 9, pp.7~ (2010)
  99. Oyaizu T, "Src tyrosine kinase inhibition prevents pulmonary ischemia-reperfusioninduced acute lung injury", Intensive Care Med, 38, pp.894~905 (2012)
  100. Antonarakis ES, "A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer", Cancer Chemotherapy and Pharmacology, 71, pp.883~892 (2013)
  101. Gangadhar TC, "Phase II study of the Src kinase inhibitor saracatinib(AZD0530)in metastatic melanoma", Invest New Drugs, 31, pp.769~773 (2013)
  102. Seltana A, "Src family kinase inhibitor PP2accelerates differentiation in human intestinal epithelial cells", Biochem Biophys Res Commun, 430, pp.1195~1200 (2013)
  103. Kim BH, "Sophoraflavanone G induces apoptosis of human cancer cells by targeting upstream signals of STATs", Biochem Pharmacol, 86, pp.950~959 (2013)
  104. Aittomäki S, "Therapeutic Targeting of the JAK", STAT Pathway, 2014, pp.114, 18~23
  105. Buchert M, "Targeting JAK kinase in solid tumors : emerging opportunities and challenges", Oncogene, 35, pp.939~ (2015)
  106. Plimack ER, "AZD1480 : a phase I study of a novel JAK2 inhibitor in solid tumors", Oncologist, 18, pp.819~820 (2013)
  107. Furtek SL, "Strategies and Approaches of Targeting STAT3 for Cancer Treatment", ACS Chem Biol, 11, pp.308~318 (2016)
  108. Puls LN, "Current status of SRC inhibitors in solid tumor malignancies", Oncologist, 16, pp.566~578 (2011)
  109. Nam S, "Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3signaling associated with apoptosis of human pancreatic cancer cells", Mol Oncol, 7, pp.369~378 (2013)
  110. Liu L, "MLS-2384, a new 6-bromoindirubin derivative with dual JAK", Src kinase inhibitory activity, suppresses growth of diverse cancer cells, 2014, pp.15, 178~184

관련 논문AI추천

Cytokine Signaling in Tumor Progression이명미, 이인무대한면역학회 · Immune Network2017 · 제17권 제4호The Diverse Function of IL-6 in Biological Processes and the Advancement of CancerSong Xiaofeng, Ying Zhou, Yongli Li, Yuan Miaomiao대한면역학회 · Immune Network2025 · 제25권 제3호Regulation of signal transducer and activator of transcription 3 activation by dual-specificity phosphatase 3Ba Reum Kim, Eunjeong Kang, Jain Ha, Sayeon Cho생화학분자생물학회 · BMB Reports2020 · 제53권 제6호Emerging role of RUNX3 in the regulation of tumor microenvironment이유미, 사랄라 마난다생화학분자생물학회 · BMB Reports2018 · 제51권 제4호Prognostic Significance of Serine-Phosphorylated STAT3 Expression in pT1–T2 Oral Tongue CarcinomaAlberto Staffieri, Claudia Staffieri, Cosimo de Filippis, Edoardo Stellini, Elena Fasanaro, Filippo Marino, Giancarlo Ottaviano, Gino Marioni, Luciano Giacomelli, Matteo Val, Rocco Cappellesso대한이비인후과학회 · Clinical and Experimental Otorhinolaryngology2015 · 제8권 제3호Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer TherapyBo Tang, Tianchi Yu, Xueying Sun연세대학교의과대학 · Yonsei Medical Journal2017 · 제58권 제3호

이 간행물의 다른 논문 (8건)

mTOR signalling pathway - A root cause for idiopathic autism?Harsha Ganesan, 조쌍구, Mohana Devi Subramaniam, Anila Venugopal, Mahalaxmi Iyer, Venkatesh Balasubramanian, Balachandar Vellingiripp. 424-4332-(trimethylammonium)ethyl (R)-3-methoxy-3-oxo-2-stearamidopropyl phosphate enhances thrombopoietin–induced megakaryocytic differentiation and plateletogenesis김재상, 이경, 이지수, 배윤수, 김주송, 진광해pp. 434-438Protective effects of N,4,5-trimethylthiazol-2-amine hydrochloride on hypoxia-induced β-amyloid production in SH-SY5Y cells한아름, 조성우, 최수영, 양지웅, 나정민pp. 439-444Surface expression of TTYH2 is attenuated by direct interaction with β-COP배연주, 류지원, 김아정, 박남미, 황은미, 김동규, 박재용, 이영선pp. 445-450High NDRG3 expression facilitates HCC metastasis by promoting nuclear translocation of β-cateninLingYan Yuan, HongZhen Zheng, JiKui Shipp. 451-456
원문 보기